New Recommendations to Improve Racial Disparities in MM Drug Trials

In a collaborative effort, researchers from the Dana-Farber Cancer Institute, the U.S. Food and Drug Administration (FDA), and the American Association for Cancer Research (AACR) released their recommendations for increasing the representation of African American patients in clinical trials for multiple myeloma (MM). The new recommendations were published in Blood Cancer Discovery. Despite literature establishing … Continue reading New Recommendations to Improve Racial Disparities in MM Drug Trials